Atai Beckley Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Srinivas G. Rao
- Full Time Employees
- 99
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 250 West 34th Street New York NY United States of America 10119
- IPO Date
- Jun 18, 2021
- CIK
- 0002081043
- Website
- ataibeckley.com
- Similar Companies
- Business
- Atai Beckley N.V. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing evidence-based mental health treatments, particularly psychedelic-based neuroplastogens and related therapies targeting unmet needs in psychiatry such as treatment-resistant depression (TRD), alcohol use disorder, social anxiety disorder, schizophrenia-associated cognitive impairment, and major depressive disorder. The company offers a diversified pipeline including BPL-003, an intranasal mebufotenin benzoate nasal spray in Phase 2b/3-ready studies for TRD and alcohol use disorder with U.S. FDA Breakthrough Therapy designation; VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) in Phase 2 for TRD with topline data expected in late 2026; EMP-01 (oral R-MDMA) in Phase 2a for social anxiety disorder with results anticipated in Q1 2026; RL-007, an oral pro-cognitive neuromodulator in Phase 2b for cognitive impairment associated with schizophrenia; ELE-101, a serotonergic psychedelic in Phase 2a for major depressive disorder; and preclinical non-hallucinogenic 5-HT2A receptor agonists EGX-A and EGX-B for TRD. Founded in 2018 and headquartered in Berlin, Germany, with additional operations in New York, London, the United States, and Canada, Atai Beckley advances scalable, rapid-acting in-clinic treatments designed for single-dose administration and short psychedelic duration to improve patient outcomes across large populations. In a major strategic development completed in November 2025, the company resulted from the all-share business combination between atai Life Sciences N.V. and Beckley Psytech Limited, valuing Beckley at approximately $390 million and integrating its assets including BPL-003 while issuing about 105 million new shares representing 31% ownership to Beckley shareholders; this followed atai's January 2024 $50 million investment acquiring a 36% stake in Beckley and a concurrent $30 million private placement from investors including Ferring Ventures and Adage Capital Partners. The transaction enhances Atai Beckley's leadership in psychedelic therapies, bolstering its intellectual property portfolio and pipeline scalability amid a global mental health crisis affecting over one billion people.
Company News
Jim Cramer Isn't Sure If There's Upside In This Health Care Stock
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders?
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly
ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.
How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu's Fashion Considers Strategic Alternatives
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies